4basebio Plc Research Collaboration

 
TIDM4BB 
 
10 June 2022 
 
                                 4basebio PLC 
 
                  ("4basebio", the "Company" or the "Group") 
 
                            Research Collaboration 
                   for treatment of Neurofibromatosis Type 1 
 
4basebio PLC (AIM: 4BB), the Cambridge based life sciences group focused on the 
development of synthetic DNA and non-viral vectors for use in the field of cell 
and gene therapies and vaccines, is pleased to announce its collaboration with 
University of Alabama ("UA") and Teesside University ("TU") in a research 
project aimed at developing an effective treatment for Neurofibromatosis Type 1 
(NF1). 
 
The universities have been awarded almost $1million from the US based Gilbert 
Family Foundation to fund a three-year research program aimed at developing a 
life-changing gene therapy with applicability to all NF1 patients and which 
will use a non-viral vector for targeted delivery of full length NF1 DNA. 4BB 
will support this project by designing and developing a 4BB non-viral HermesT 
vector and 4BB hpDNAT sequence as payload for UA and TU. 
 
NF1 is a genetic condition which causes usually benign tumours to develop 
anywhere in the nervous system, including the brain, spinal cord and nerves. 
Complications of NF1 are many and can include learning difficulties, speech 
difficulties and skeletal malformations, heart and blood vessel 
(cardiovascular) problems, loss of vision, and severe pain.  NF1 is caused by 
mutations in the NF1 gene which regulates the production of neurofibromin 
protein. 
 
Dr Heikki Lanckriet, CEO and CSO for 4basebio said: "We are very pleased to be 
able to support this research project and are delighted that this exciting 
collaboration between academia and industry has been recognised with the award 
from the Gilbert Family Foundation." 
 
Dr Deeann Wallis, PI at University of Alabama, said: "I'm excited about 
partnering with 4basebio and utilizing both their non-viral HermesT vector and 
hpDNAT sequence as payload to target delivery of NF1 as a therapeutic for those 
with Neurofibromatosis Type I.  Such a combination of technologies is an 
attractive therapeutic approach for individuals with few options." 
 
Dr Linda Popplewell, Professor of Genetic Medicine at National Horizon Centre, 
Teesside University, said 'The opportunity to work with 4basebio on this 
Gilbert Family Foundation GTi award is exceptionally exciting. Access to their 
impressive technologies and their application to NF1 has the potential to be 
transformative". 
 
For further enquiries, please contact: 
 
4basebio PLC                                                     [phone] 
7943 
 
Heikki Lanckriet 
 
Nominated Adviser                                                 +44 (0)20 
7213 0880 
 
Cairn Financial Advisers LLP 
 
Jo Tuner / Sandy Jamieson 
 
Broker                                                                +44 (0)20 
7220 0500 
 
finnCap Ltd 
 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe 
 
Notes to Editors 
 
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic 
DNA for cell and gene therapies and DNA vaccines and providing solutions for 
effective and safe delivery of these DNA based products to patients. It is the 
intention of the Company to become a market leader in the manufacture and 
supply of high purity, synthetic DNA for research, therapeutic and 
pharmacological use and develop non-viral vectors for the efficient delivery of 
payloads. The immediate objectives of 4basebio are to continue the validation 
of its DNA products and HermesT technology and commence revenue generation 
during 2022. 4basebio also continues to advance its collaborations to 
facilitate the functional validation of its DNA based products and cell and 
gene delivery solutions. 
 
Forward-looking statements 
 
This announcement may contain certain statements about the future outlook for 
the 4basebio.  Although the directors believe their expectations are based on 
reasonable assumptions, any statements about future outlook may be influenced 
by factors that could cause actual outcomes and results to be materially 
different. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

June 10, 2022 02:00 ET (06:00 GMT)